Sökning: WFRF:(Korecka M.) > Update on the bioma...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05103naa a2200937 4500 | |
001 | oai:gup.ub.gu.se/127470 | |
003 | SwePub | |
008 | 240528s2010 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/1274702 URI |
024 | 7 | a https://doi.org/10.1016/j.jalz.2010.03.0082 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a for2 swepub-publicationtype |
100 | 1 | a Trojanowski, John Q4 aut |
245 | 1 0 | a Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. |
264 | c 2010-05 | |
264 | 1 | b Wiley,c 2010 |
520 | a Here, we review progress by the Penn Biomarker Core in the Alzheimer's Disease Neuroimaging Initiative (ADNI) toward developing a pathological cerebrospinal fluid (CSF) and plasma biomarker signature for mild Alzheimer's disease (AD) as well as a biomarker profile that predicts conversion of mild cognitive impairment (MCI) and/or normal control subjects to AD. The Penn Biomarker Core also collaborated with other ADNI Cores to integrate data across ADNI to temporally order changes in clinical measures, imaging data, and chemical biomarkers that serve as mileposts and predictors of the conversion of normal control to MCI as well as MCI to AD, and the progression of AD. Initial CSF studies by the ADNI Biomarker Core revealed a pathological CSF biomarker signature of AD defined by the combination of Abeta1-42 and total tau (T-tau) that effectively delineates mild AD in the large multisite prospective clinical investigation conducted in ADNI. This signature appears to predict conversion from MCI to AD. Data fusion efforts across ADNI Cores generated a model for the temporal ordering of AD biomarkers which suggests that Abeta amyloid biomarkers become abnormal first, followed by changes in neurodegenerative biomarkers (CSF tau, F-18 fluorodeoxyglucose-positron emission tomography, magnetic resonance imaging) with the onset of clinical symptoms. The timing of these changes varies in individual patients due to genetic and environmental factors that increase or decrease an individual's resilience in response to progressive accumulations of AD pathologies. Further studies in ADNI will refine this model and render the biomarkers studied in ADNI more applicable to routine diagnosis and to clinical trials of disease modifying therapies. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Psykiatri0 (SwePub)302152 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Psychiatry0 (SwePub)302152 hsv//eng |
653 | a Alzheimer Disease | |
653 | a blood | |
653 | a cerebrospinal fluid | |
653 | a diagnosis | |
653 | a Amyloid beta-Protein | |
653 | a metabolism | |
653 | a Aniline Compounds | |
653 | a diagnostic use | |
653 | a Apolipoproteins E | |
653 | a genetics | |
653 | a Biological Markers | |
653 | a blood | |
653 | a cerebrospinal fluid | |
653 | a Cognition Disorders | |
653 | a blood | |
653 | a cerebrospinal fluid | |
653 | a Cross-Sectional Studies | |
653 | a Diagnostic Imaging | |
653 | a methods | |
653 | a trends | |
653 | a Homocysteine | |
653 | a metabolism | |
653 | a Humans | |
653 | a Isoprostanes | |
653 | a metabolism | |
653 | a Peptide Fragments | |
653 | a metabolism | |
653 | a Positron-Emission Tomography | |
653 | a methods | |
653 | a Prospective Studies | |
653 | a Reproducibility of Results | |
653 | a Thiazoles | |
653 | a diagnostic use | |
653 | a tau Proteins | |
653 | a metabolism | |
700 | 1 | a Vandeerstichele, Hugo4 aut |
700 | 1 | a Korecka, Magdalena4 aut |
700 | 1 | a Clark, Christopher M4 aut |
700 | 1 | a Aisen, Paul S4 aut |
700 | 1 | a Petersen, Ronald C4 aut |
700 | 1 | a Blennow, Kaj,d 1958u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xbleka |
700 | 1 | a Soares, Holly4 aut |
700 | 1 | a Simon, Adam4 aut |
700 | 1 | a Lewczuk, Piotr4 aut |
700 | 1 | a Dean, Robert4 aut |
700 | 1 | a Siemers, Eric4 aut |
700 | 1 | a Potter, William Z4 aut |
700 | 1 | a Weiner, Michael W4 aut |
700 | 1 | a Jack, Clifford R4 aut |
700 | 1 | a Jagust, William4 aut |
700 | 1 | a Toga, Arthur W4 aut |
700 | 1 | a Lee, Virginia M-Y4 aut |
700 | 1 | a Shaw, Leslie M4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi4 org |
773 | 0 | t Alzheimer's & dementia : the journal of the Alzheimer's Associationd : Wileyg 6:3, s. 230-8q 6:3<230-8x 1552-5279 |
773 | 0 | t Alzheimer's & Dementiad : Wileyg 6:3, s. 230-8q 6:3<230-8x 1552-5260 |
856 | 4 | u https://europepmc.org/articles/pmc2867838?pdf=render |
856 | 4 8 | u https://gup.ub.gu.se/publication/127470 |
856 | 4 8 | u https://doi.org/10.1016/j.jalz.2010.03.008 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy